Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03016871
Title Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Carboplatin + Etoposide + Ifosfamide + Nivolumab

Age Groups: adult | senior | child
Covered Countries USA


No variant requirements are available.